CG Oncology Inc. 发布的最新数据显示，在意向治疗（ITT）人群中，其疗法展现出了令人瞩目的高分级无事件生存率。具体而言，在治疗后的3个月时间点，该比率高达96.0%；而到第6个月时，这一数据依然保持在89.5%的强劲水平。这些结果突显了该疗法在短期至中期随访中的有效性与持久性潜力。
CG Oncology Inc. 发布的最新数据显示，在意向治疗（ITT）人群中，其疗法展现出了令人瞩目的高分级无事件生存率。具体而言，在治疗后的3个月时间点，该比率高达96.0%；而到第6个月时，这一数据依然保持在89.5%的强劲水平。这些结果突显了该疗法在短期至中期随访中的有效性与持久性潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.